LU92939I2 - Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable - Google Patents
Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable Download PDFInfo
- Publication number
- LU92939I2 LU92939I2 LU92939C LU92939C LU92939I2 LU 92939 I2 LU92939 I2 LU 92939I2 LU 92939 C LU92939 C LU 92939C LU 92939 C LU92939 C LU 92939C LU 92939 I2 LU92939 I2 LU 92939I2
- Authority
- LU
- Luxembourg
- Prior art keywords
- isavuconazonium
- salt
- isavuconbazole
- sulphate
- hydrate
- Prior art date
Links
- RSWOJTICKMKTER-QXLBVTBOSA-N isavuconazonium Chemical compound CNCC(=O)OCC1=CC=CN=C1N(C)C(=O)OC(C)[N+]1=CN(C[C@@](O)([C@@H](C)C=2SC=C(N=2)C=2C=CC(=CC=2)C#N)C=2C(=CC=C(F)C=2)F)N=C1 RSWOJTICKMKTER-QXLBVTBOSA-N 0.000 title 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 title 1
- 150000001450 anions Chemical class 0.000 title 1
- 229960004922 isavuconazonium Drugs 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 229910021653 sulphate ion Inorganic materials 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pharmacology & Pharmacy (AREA)
- Communicable Diseases (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cephalosporin Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99121694 | 1999-11-02 | ||
| PCT/EP2000/010524 WO2001032652A2 (fr) | 1999-11-02 | 2000-10-25 | Dérivés carbamoyloxyalkyl-azolium n-substitués |
| EP00992946A EP1280795B1 (fr) | 1999-11-02 | 2000-10-25 | Derives carbamoyloxyalkyl-azolium n-substitues |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| LU92939I2 true LU92939I2 (fr) | 2016-03-07 |
Family
ID=8239312
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LU92939C LU92939I2 (fr) | 1999-11-02 | 2016-01-06 | Isavuconbazole en tant que sulfate d'isavuconazonium ou en tant que sel d'isavuconazonium avec tout autre anion pharmaceutiquement acceptable, optionnellement sous forme d'un sel, hydrate ou solvate pharmacuetiquement acceptable |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP1280795B1 (fr) |
| JP (1) | JP3787307B2 (fr) |
| KR (1) | KR100449797B1 (fr) |
| CN (1) | CN1185230C (fr) |
| AR (1) | AR029403A1 (fr) |
| AT (1) | ATE291575T1 (fr) |
| AU (1) | AU777859B2 (fr) |
| BE (1) | BE2016C007I2 (fr) |
| BR (1) | BRPI0015254C1 (fr) |
| CA (2) | CA2388320C (fr) |
| CY (1) | CY2016002I2 (fr) |
| DE (1) | DE60018989T2 (fr) |
| DK (1) | DK1280795T3 (fr) |
| ES (1) | ES2238341T3 (fr) |
| FR (1) | FR15C0096I2 (fr) |
| LU (1) | LU92939I2 (fr) |
| MX (1) | MXPA02004145A (fr) |
| NL (1) | NL300791I1 (fr) |
| PT (1) | PT1280795E (fr) |
| TR (1) | TR200201205T2 (fr) |
| WO (1) | WO2001032652A2 (fr) |
| ZA (1) | ZA200203003B (fr) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY148805A (en) | 2002-10-16 | 2013-05-31 | Takeda Pharmaceutical | Controlled release preparation |
| KR101493546B1 (ko) | 2007-08-21 | 2015-02-16 | 바실리어 파마슈티카 아게 | 항균 조성물 |
| EP2723452A2 (fr) | 2011-06-22 | 2014-04-30 | Vyome Biosciences Pvt Ltd | Promédicaments antifongiques et antibactériens à base d'un conjugué |
| US20160128944A1 (en) | 2013-06-04 | 2016-05-12 | Vyome Biosciences Pvt. Ltd. | Coated particles and compositions comprising same |
| CN104230894B (zh) * | 2013-06-06 | 2016-08-24 | 南京华威医药科技开发有限公司 | 三唑类化合物 |
| US20170290333A1 (en) * | 2014-12-30 | 2017-10-12 | Dow Agrosciences Llc | Picolinamide compounds with fungicidal activity |
| CN106032356B (zh) * | 2015-03-13 | 2018-09-14 | 江苏正大丰海制药有限公司 | 一种[n-甲基-吡啶-2-基]氨基甲酸-1-氯乙酯的制备方法 |
| CN104974143A (zh) * | 2015-05-12 | 2015-10-14 | 深圳致君制药有限公司 | 一种季铵盐类化合物、其制备方法以及用途 |
| CN106467519B (zh) * | 2015-08-17 | 2019-08-13 | 南京华威医药科技集团有限公司 | 一种水溶性三唑化合物 |
| CN106467534B (zh) * | 2015-08-17 | 2019-10-11 | 江苏奥赛康药业有限公司 | 一种硫酸艾沙康唑鎓化合物及其药物组合物 |
| CN106565699B (zh) * | 2015-10-10 | 2019-07-26 | 江苏正大丰海制药有限公司 | 一种艾沙康唑硫酸盐晶体及其制备方法 |
| WO2018067702A1 (fr) | 2016-10-04 | 2018-04-12 | Massachusetts Institute Of Technology | Copolymères en forme de goupillon et leurs utilisations |
| EP3584245A4 (fr) * | 2017-02-17 | 2020-08-26 | Wuhan LL Science And Technology Development Co., Ltd. | Dérivé antibactérien de triazole, composition pharmaceutique et utilisation associées |
| CN106916152B (zh) * | 2017-04-27 | 2019-09-17 | 扬子江药业集团有限公司 | 氧化还原反应制备艾沙康唑鎓单硫酸盐的方法 |
| WO2019006426A2 (fr) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | Macromonomères multifonctionnels ramifiés et polymères apparentés et utilisations associées |
| WO2019006425A1 (fr) | 2017-06-30 | 2019-01-03 | Massachusetts Institute Of Technology | Agents d'imagerie de polymères en étoile à bras de brosse et leurs utilisations |
| US10368502B2 (en) | 2017-09-25 | 2019-08-06 | Multiple Energy Technologies Llc | Bioceramic and carbon-based hydroponic systems, methods and devices |
| CN110317165A (zh) * | 2018-03-28 | 2019-10-11 | 上海医药工业研究院 | 一种药物中间体2-甲胺基-3-吡啶甲醇的制备方法 |
| WO2019200367A1 (fr) | 2018-04-13 | 2019-10-17 | Massachusetts Institute Of Technology | Promédicaments à brosse et leurs utilisations |
| CN110551064B (zh) * | 2018-06-01 | 2021-01-01 | 重庆世森医药科技有限公司 | 艾沙康唑硫酸酯及其中间体的制备方法 |
| MX2021001116A (es) | 2018-08-01 | 2021-03-31 | Basilea Pharm Int Ag | Metodos para purificar sulfato de isavuconazonio. |
| WO2020037236A1 (fr) | 2018-08-17 | 2020-02-20 | Massachusetts Institute Of Technology | Polymères dégradables d'un éther de silyle cyclique et utilisations associées |
| CN110128420A (zh) * | 2019-05-08 | 2019-08-16 | 阴启明 | 硫酸氢根/硫酸根型阴离子交换技术制备艾沙康唑鎓单硫酸盐的方法 |
| WO2021037597A1 (fr) | 2019-08-26 | 2021-03-04 | Synthon B.V. | Sels d'isavuconazonium et leur procédé de préparation |
| AU2020368453A1 (en) * | 2019-10-16 | 2022-04-21 | Massachusetts Institute Of Technology | Brush prodrugs and uses thereof |
| WO2021141662A1 (fr) | 2020-01-10 | 2021-07-15 | Massachusetts Institute Of Technology | Molécules chimériques ciblant la protéolyse (protacs) à bras fonctionnels et leurs utilisations |
| JP7454905B2 (ja) * | 2021-09-28 | 2024-03-25 | 旭化成ファーマ株式会社 | 有効成分であるイサブコナゾール又はそのプロドラッグを含有する真菌症治療及び／又は予防剤 |
| JP7570382B2 (ja) | 2021-09-28 | 2024-10-21 | 旭化成ファーマ株式会社 | エアベント付き輸液フィルタを備える点滴静脈投与用輸液セット |
| EP4452933A1 (fr) | 2021-12-20 | 2024-10-30 | Massachusetts Institute of Technology | Conjugués biomolécule-polymère-agent pharmaceutique pour administrer l'agent pharmaceutique |
| EP4289840A1 (fr) | 2022-06-07 | 2023-12-13 | Zaklady Farmaceutyczne Polpharma S.A. | Procede de preparation de sulfate d'isavuconazonium |
| WO2024094329A1 (fr) | 2022-11-01 | 2024-05-10 | Basilea Pharmaceutica International Ag, Allschwil | Préparation de capsule sous emballage coque contenant du sulfate d'isavuconazonium |
| WO2024189550A1 (fr) * | 2023-03-13 | 2024-09-19 | Apitoria Pharma Private Limited | Procédé de préparation de sulfate d'isavuconazonium et ses formes cristallines |
| AR134544A1 (es) | 2023-11-30 | 2026-01-28 | Basilea Pharmaceutica Int Ag Allschwil | Combinaciones farmacéuticas para su uso en el tratamiento de infecciones fúngicas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20010005792A (ko) * | 1997-03-31 | 2001-01-15 | 다케다 야쿠힌 고교 가부시키가이샤 | 아졸 화합물, 이의 제조 방법 및 용도 |
| JP3108997B2 (ja) * | 1997-03-31 | 2000-11-13 | 武田薬品工業株式会社 | アゾール化合物、その製造法および用途 |
| WO1999045008A1 (fr) * | 1998-03-06 | 1999-09-10 | F. Hoffmann-La Roche Ag | Derives 3-[4-(4-cyanophenyl)thiazol-2-y)]-1-(1h-1,2,4-triazol-1-yl)-butan-2-ol possedant une activite antifongique |
-
2000
- 2000-10-25 ES ES00992946T patent/ES2238341T3/es not_active Expired - Lifetime
- 2000-10-25 BR BRPI0015254A patent/BRPI0015254C1/pt not_active IP Right Cessation
- 2000-10-25 WO PCT/EP2000/010524 patent/WO2001032652A2/fr not_active Ceased
- 2000-10-25 CN CNB008153299A patent/CN1185230C/zh not_active Expired - Lifetime
- 2000-10-25 EP EP00992946A patent/EP1280795B1/fr not_active Expired - Lifetime
- 2000-10-25 AU AU28352/01A patent/AU777859B2/en not_active Expired
- 2000-10-25 MX MXPA02004145A patent/MXPA02004145A/es active IP Right Grant
- 2000-10-25 TR TR2002/01205T patent/TR200201205T2/xx unknown
- 2000-10-25 DE DE60018989T patent/DE60018989T2/de not_active Expired - Lifetime
- 2000-10-25 CA CA002388320A patent/CA2388320C/fr not_active Expired - Lifetime
- 2000-10-25 JP JP2001534803A patent/JP3787307B2/ja not_active Expired - Lifetime
- 2000-10-25 AT AT00992946T patent/ATE291575T1/de active
- 2000-10-25 DK DK00992946T patent/DK1280795T3/da active
- 2000-10-25 CA CA2680292A patent/CA2680292C/fr not_active Expired - Lifetime
- 2000-10-25 KR KR10-2002-7005574A patent/KR100449797B1/ko not_active Expired - Lifetime
- 2000-10-25 PT PT00992946T patent/PT1280795E/pt unknown
- 2000-10-31 AR ARP000105739A patent/AR029403A1/es active IP Right Grant
-
2002
- 2002-04-16 ZA ZA200203003A patent/ZA200203003B/xx unknown
-
2015
- 2015-12-29 FR FR15C0096C patent/FR15C0096I2/fr active Active
-
2016
- 2016-01-06 LU LU92939C patent/LU92939I2/fr unknown
- 2016-01-26 NL NL300791C patent/NL300791I1/nl unknown
- 2016-02-03 CY CY2016002C patent/CY2016002I2/el unknown
- 2016-02-26 BE BE2016C007C patent/BE2016C007I2/fr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LU91681I2 (fr) | "Eltrombopag,éventuellement sous forme d'un sel oud'un solvate (y compris sous forme d'un hydrate) pharmaceutiquement acceptable (REVOLADE)" | |
| LU91372I2 (fr) | Retapamulin optionnellement sous forme d'un sel pharmaceutiquement acceptable (altargo) | |
| LU91442I2 (fr) | "Varénicline, optionnellement sous forme d'un sel pharmaceutiquement acceptable, y compris le sel tartrate" | |
| PT2264018E (pt) | Derivados de tioflavina para uso no diagnóstico da doença de alzheimer | |
| LU92428I2 (fr) | Bosutinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable | |
| DE60031959D1 (de) | Im riser angebrachter rotierender kontrollkopf | |
| LU92397I2 (fr) | Vortioxétine ou un sel d'addition d'acide de celui-ci pharmaceutiquement acceptable | |
| LU92407I2 (fr) | Afatinib, éventuellement sous la forme d'un sel pharmaceutiquement acceptable, y compris le sel dimaléate | |
| LU91306I2 (fr) | Mitratapide, optionnellement sous forme d'un sel d'addition acide pharmaceutiquement acceptable (YARVITAN) | |
| LU90426I2 (fr) | Abacavir facultativement sous la forme d'un sel pharmaceutiquement acceptable ou d'un d-rive y compris le sulfate d'abacavir | |
| IS4394A (is) | Meðferðaefnasambönd, lyfjafræðilega hæf sölt og samsetningar sem innihalda efnasamböndin, ásamt notkun þeirra | |
| LU92699I2 (fr) | Bazédoxifène, éventuellement sous la forme d'un sel pharmaceutiquement, acceptable tel que le sel d'acétate, et d'estrogènes conjugués | |
| ATE316781T1 (de) | Antivirale feste dispersionen | |
| DE3772883D1 (de) | Hydrophob modifizierte hydroxyethylcellulose in waesserigen dispersionen. | |
| LU91027I2 (fr) | Dutasteride optionnellement sous forme d'un solvate pharmaceutiquement acceptable | |
| MXPA03004714A (es) | Sales de una isotiazol-4-carboxamida y su uso como agentes de antihiperproliferacion. | |
| FR2799148B3 (fr) | Agrafeuse avec indication de la quantite d'agrafes restantes | |
| IL156499A0 (en) | Quinuclidine carbamate derivatives and their use as m3 antagonists | |
| IL150475A0 (en) | Pharmaceutical composition comprising pemetrexed together with monothioglycerol l-cystein or thioglycolic acid | |
| HUP0102946A3 (en) | Composition comprising at least one uv screening agent and a flavynium salt which is unsubstituted in position 3, for colouring the skin and use its | |
| PL357256A1 (en) | Ship's hull bowl shape | |
| USD463074S1 (en) | Retractable leash saddle | |
| HUP0203611A3 (en) | 14,15-beta-methylene substituted androgens and their use for preparation of the medicaments | |
| EP1274431A4 (fr) | Composes 10, 11-difluoromethylenedioxycamptothecine avec inhibition de topoisomerase i | |
| FR2854795B1 (fr) | Composition cosmetique visant a creer une variation de couleur avec l'angle d'observation |